Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

WIB_icon

Study Identifies Genetic Markers That Predict Radiation-Induced Breast Cancer After Hodgkin Lymphoma

The risk of developing breast cancer is high in women with Hodgkin lymphoma (HL) who have undergone chest radiotherapy (RT), but the role of...

ECHELON-2: Brentuximab Vedotin Combination Outperforms CHOP for Peripheral T-Cell Lymphomas

Results from the phase III ECHELON-2 trial showed that brentuximab vedotin added to a combination of cyclophosphamide, doxorubicin, and prednisone (BV+CHP) nearly doubled progression-free...

Four Cycles as Effective as Six Cycles of Chemotherapy for Favorable-Risk DLBCL

While young patients with diffuse large B-cell lymphoma (DLBCL) are typically treated with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone), results from...

First Biosimilar for Rituximab Gains Approval

The FDA approved rituximab-abbs, the first biosimilar of rituximab, for the treatment of adult patients with CD20-positive, B-cell non-Hodgkin lymphoma (NHL). This marks the...

Duvelisib Approved for Patients with CLL or SLL

The FDA has approved the PI3K inhibitor duvelisib for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...

FDA Approves NGS-Based Test for Patients With ALL or MM

The FDA authorized the next-generation sequencing (NGS)–based ClonoSEQ assay for the measurement of minimal residual disease (MRD) in patients with acute lymphocytic leukemia (ALL)...

U.K. Panel Rejects Venetoclax-Rituximab Combo for CLL

The U.K.’s National Institute for Health and Care Excellence (NICE) has published draft guidance rejecting the combination of venetoclax and rituximab for the treatment...

Clinical Trials of Leukemia and Lymphoma Drug Placed on Hold

Pharmaceutical manufacturer Affimed has halted two trials of its CD19/CD3-targeting T-cell engager AFM11 following reports of three serious adverse events (AEs), including one patient...

Patient Dies After Developing Resistance to CAR T-Cell Therapy

A young patient with B-cell acute lymphocytic leukemia who received chimeric antigen receptor (CAR) T-cell therapy developed a resistance to his treatment, according to...

European Commission Expands Blinatumomab’s Approval for ALL

The European Commission (EC) has approved an expanded indication for blinatumomab to include the treatment of pediatric patients with Philadelphia chromosome–negative (Ph-negative) relapsed or...
Advertisement

Current Issue

February 2019, Volume 5, Issue 3

This issue features a look at the unique challenges of developing treatments for orphan diseases, more coverage of the 2018 ASH annual meeting, and more.